FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy(Centre de Recherche en Automatique de Nancy), Françoise Desseigne(Centre Léon Bérard), Marc Ychou(CEA Valduc), Olivier Bouché(Centre Hospitalier Universitaire de Reims), Rosine Guimbaud(Institut Claudius Regaud), Y. Bécouarn(Institut Bergonié), Antoine Adenis(Centre Oscar Lambret), Jean‐Luc Raoul(Centre Eugène Marquis), S. Gourgou-Bourgade(CEA Valduc), Christelle de la Fouchardière(Centre Léon Bérard), Jaafar Bennouna, Jean‐Baptiste Bachet(Hôpital Ambroise-Paré), Faiza Khemissa-Akouz(Centre Hospitalier de Perpignan), Denis Péré-Vergé(Hôpital de la Croix-Rousse), Catherine Delbaldo(Centre Hospitalier Universitaire Henri-Mondor), Eric Assénat(Hôpital Saint Eloi), Bruno Chauffert(Centre Georges François Leclerc), Pierre Michel(Université de Rouen Normandie), C. Montoto-Grillot(UniCancer Group), Michel Ducreux(Institut Gustave Roussy)
Cited by 7,715Open Access
Abstract
International audience
Related Papers
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al.|JNCI Journal of the National Cancer Institute|2000|15.7k
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Martin M. Oken, Richard H. Creech, Douglass C. Tormey et al.|American Journal of Clinical Oncology|1982|11.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al.|Journal of Clinical Oncology|1997|5.9k